Compare DraftKings Inc (DKNG) vs TG Therapeutics Inc (TGTX) Price & Performance

DraftKings (DKNG) trades at $19.58, down 7.4% recently and near a 52-week low of $18.95, reflecting bearish technical signals. The company achieved profitability in 2025 with $6.05B revenue and $3.71M net income, but Q2 2026 EPS missed estimates. Analyst consensus remains strongly bullish with a $33.13 price target, though high valuation multiples and recent earnings volatility pose concerns.

Long-term prospects are supported by revenue growth and strategic initiatives like the DKeX rollout and NHL sponsorship, targeting $1B EBITDA in 2026. However, risks include competitive pressures, regulatory uncertainty in markets like Brazil, and the stock's sensitivity to growth deceleration. Investors should weigh strong analyst optimism against fundamental execution risks.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.